Presentation is loading. Please wait.

Presentation is loading. Please wait.

First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone.

Similar presentations


Presentation on theme: "First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone."— Presentation transcript:

1 First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL) or their combination (L + T) in the adjuvant treatment of HER2-positive early breast cancer (EBC) Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

2 TARGETING HER2 IN BREAST CANCER: EVOLVING CONCEPTS Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

3 Slide 3 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

4 Slide 4 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

5 Slide 5 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

6 Slide 6 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

7 Slide 7 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

8 Primary Endpoint Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

9 SECONDARY EndpointS Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

10 STAtiStical considerations Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

11 Current Analysis Plan Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

12 Slide 12 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

13 CONSORT TABLE Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

14 Slide 14 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

15 Distribution of the Stratification Factors by Treatment Arm Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

16 Distribution of patient characteristics by Treatment Arm Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

17 Slide 17 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

18 DISEASE-FREE SURVIVAL (DFS) ANALYSIS Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

19 DFS BY Hormone Receptor Status Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

20 DFS by Chemotherapy Timing Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

21 OVERALL SURVIVAL (OS) ANALYSIS Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

22 DFS NON-INFERIORITY ANALYSIS Note: Null hypothesis hazard ratio is 1.11 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

23 Slide 23 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

24 PROPORTION OF PATIENTS RECEIVING ≥ 85% OF THE PLANNED DOSE OF ANTI-HER2 DRUGS Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

25 Slide 25 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

26 MAIN DIFFERENCES IN AEs BY TREATMENT ARM Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

27 CARDIAC SAFETY Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

28 CONCLUSIONS (I) Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

29 CONCLUSIONS (II) Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

30 Acknowledgements Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting


Download ppt "First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone."

Similar presentations


Ads by Google